Page 233 - 82_ex2

Pharmacological approaches in obesity treatment
http://www.fda.gov/downloads/AdvisoryCommittees/
CommitteesMeetingMaterials/Drugs/Endocrinologica
ndMetabolicDrugsAdvisoryCommittee/UCM303352p
df. [Accessed July 3, 2013];
35. Ioannides-Demos LL, Proietto J, McNeil JJ
Pharmacotherapy for obesity. Drugs 2005; 65: 1391-
1418.
36. Hampp C, Kang EM, Borders-Hemphill V. Use of
prescription antiobesity drugs in the United States.
Pharmacotherapy 2013; 33: 1299-1307.
37. Hendricks EJ, Greenway FL, Westman EC, Gupta AK
Blood pressure and heart rate effects, weight loss and
maintenance during long-term phentermine
pharmacotherapy for obesity. Obesity (Silver Spring)
2011; 19: 2351-60.
38. Cercato C, Roizenblatt VA, Leança CC, et al. A
randomized double-blind placebo-controlled study of
the long-term efficacy and safety of diethylpropion in
the treatment of obese subjects. Int J Obes (London)
2009; 33: 857-65.
39. Haddock CK, Poston WS, Dill PL, Foreyt JP,
Ericsson M. Pharmacotherapy for obesity: a
quantitative analysis of four decades of published
randomized clinical trials. Int J Obes Relat Metab
Disord 2002; 26: 262-73.
40. Munro JF, MacCuish AC, Wilson EM, Duncan LJ.
Comparison of continuous and intermittent anorectic
therapy in obesity. Br Med J 1968; 1: 352-4.
41. Runyan JW. Observations on the use of
phendimetrazine, a new anorexigenic agent, in obese
diabetics. Curr Ther Res Clin Exp 1962; 4: 270-5.
42. Hadler AJ. Sustained-action phendimetrazine in
obesity. J Clin Pharmacol J New Drugs 1968; 8: 113-
7.
43. Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher
JA. Safety profile of sustained-release bupropion in
depression: results of three clinical trials. Clin Ther
1999; 21: 454-63.
44. Croft H, Houser T, Jamerson B. Lack of weight gain
in patients taking bupropion SR: a 1-year placebo-
controlled study in patients with major depression.
Obes Res 2000; 9: 47S.
45. Greenway FL, Fujioka K, Plodkowski RA, et al.
Effect of naltrexone plus bupropion on weight loss in
overweight and obese adults (COR–I): A multicentre,
randomised, double-blind, placebo-controlled, phase 3
trial. Lancet 2010; 376: 595-605.
46. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss
with naltrexone SR/bupropion SR combination
therapy as an adjunct to behavior modification: the
COR-BMOD trial. Obesity (Silver Spring) 2011; 19:
110-20.
47. Apovian CM, Aronne L, Rubino D, et al. A
randomized, phase 3 trial of naltrexone SR/bupropion
SR on weight and obesity-related risk factors (COR-
II). Obesity (Silver Spring) 2013; 21: 935-43.
@Real Academia Nacional de Farmacia. Spain
48. Hollander P, Gupta AK, Plodkowski R, et al; COR-
Diabetes Study Group. Effects of naltrexone
sustained-release/bupropion sustained-release
combination therapy on body weight and glycemic
parameters in overweight and obese patients with type
2 diabetes. Diabetes Care 2013; 36: 4022-9.
49. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal
KR. Orlistat in the long-term treatment of obesity in
primary care settings. Arch Fam Med 2000; 9: 160-7.
50. Swinburn BA, Carey D, Hills AP, et al. Effect of
orlistat on cardiovascular disease risk in obese adults.
Diabetes Obes Metab 2005; 7: 254-62.
51. Hollander PA, Elbein SC, Hirsch IB, et al. Role of
orlistat in the treatment of obese patients with type 2
diabetes. A 1-year randomized double-blind study.
Diabetes Care 1998; 21: 1288-94.
52. Rossner S, Sjostrom L, Noack R, Meinders AE,
Noseda G. Weight loss, weight maintenance, and
improved cardiovascular risk factors after 2 years
treatment with orlistat for obesity. European Orlistat
Obesity Study Group. Obes Res 2000; 8: 49-61.
53. Davidson MH, Hauptman J, DiGirolamo M, et al.
Weight control and risk factor reduction in obese
subjects treated for 2 years with orlistat: a randomized
controlled trial. JAMA 1999; 281: 235-42.
54. Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli
P. Effects of 1-year orlistat treatment compared to
placebo on insulin resistance parameters in patients
with type 2 diabetes. J Clin Pharm Ther 2012; 37:
187-95.
55. Sjostrom L, Rissanen A, Andersen T, et al.
Randomised placebo-controlled trial of orlistat for
weight loss and prevention of weight regain in obese
patients. European Multicentre Orlistat Study Group.
Lancet 1998; 352: 167-72.
56. Tonstad S, Pometta D, Erkelens DW, et al. The effect
of the gastrointestinal lipase inhibitor, orlistat, on
serum lipids and lipoproteins in patients with primary
hyperlipidaemia. Eur J Clin Pharmacol 1994; 46: 405-
10.
57. Zhou YH, Ma XQ, Wu C, et al. Effect of anti-obesity
drug on cardiovascular risk factors: a systematic
review and meta-analysis of randomized controlled
trials. PLoS One 2012; 7: e39062.
58. Johansson K, Sundstrom J, Neovius K, Rossner S,
Neovius M. Long-term changes in blood pressure
following orlistat and sibutramine treatment: a meta-
analysis. Obes Res 2010; 11: 777-91.
59. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L.
XENical in the prevention of diabetes in obese
subjects (XENDOS) study: a randomized study of
orlistat as an adjunct to lifestyle changes for the
prevention of type 2 diabetes in obese patients.
Diabetes Care 2004; 27: 155-61.
60. Li Z, Maglione M, Tu W, et al. Meta-analysis:
pharmacologic treatment of obesity. Ann Intern Med
2005; 142: 532-46.
223